Christopher T. Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher T. Martin has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Amy Criego
International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA
1 shared publication - Anders L. Carlson
HealthPartners Institute Minneapolis Minnesota USA
1 shared publication - Richard M. Bergenstal
International Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA
1 shared publication
Latest Publications
- Open Access
- 27 June 2019
- Published by Springer Nature in Current Diabetes Reports
- Vol. 19 (8) , 1-9
Advanced Technology in the Management of Diabetes: Which Comes First—Continuous Glucose Monitor or Insulin Pump?
Purpose of Review In this article, we consider advanced technologies for the management of diabetes. Recent Findings Specifically, we pose the question of which should come first: an insulin pump (CSII) or a continuous glucose monitor (CGM)? Historical perspective on both insulin delivery and glucose measurement is provided. Recently published clinical trials are reviewed. Practical issues including quality of life, patient education, and out-of-pocket cost are discussed. Summary Based on available evidence and clinical experience, we favor CGM as a first-line technology recommendation for the treatment of type 1 diabetes (T1D).
- 27 June 2019
- Published by Springer Nature in Current Diabetes Reports
- Vol. 19 (8) , 1-9
Open AccessAdvanced Technology in the Management of Diabetes: Which Comes First—Continuous Glucose Monitor or Insulin Pump?
Purpose of Review In this article, we consider advanced technologies for the management of diabetes. Recent Findings Specifically, we pose the question of which should come first: an insulin pump (CSII) or a continuous glucose monitor (CGM)? Historical perspective on both insulin delivery and glucose measurement is provided. Recently published clinical trials are reviewed. Practical issues including quality of life, patient education, and out-of-pocket cost are discussed. Summary Based on available evidence and clinical experience, we favor CGM as a first-line technology recommendation for the treatment of type 1 diabetes (T1D).